Acura Pharma (ACUR) Receives Preliminary Review Letter from FDA Related to NDA for Acurox(r)
Tweet Send to a Friend
Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) announced today receipt from the U.S. FDA of a review letter related to our New ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
